Interventions for rosacea

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2015, Pages

  van Zuuren, Esther J ^a   Fedorowicz, Zbys ^b   Carter, Ben ^c   van der Linden, Mireille M D ^d   Charland, Lyn ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bahrain Branch ^*  (Bahrain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BRIMONIDINE; CLINDAMYCIN PHOSPHATE; CYCLOSPORIN A; DOXYCYCLINE; ISOTRETINOIN; IVERMECTIN; METRONIDAZOLE; MINOCYCLINE; PLACEBO; RETINOIC ACID; TETRACYCLINE; ANTIINFECTIVE AGENT; CYCLOSPORIN; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID; EYE DROPS; QUINOXALINE DERIVATIVE;

ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LOW RISK PATIENT; MEDICAL ASSESSMENT; META ANALYSIS; NEODYMIUM YAG LASER; PATIENT SAFETY; PHOTOTHERAPY; PRIORITY JOURNAL; PUSTULE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; ROSACEA; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TELANGIECTASIA; TREATMENT RESPONSE; FEMALE; MALE; MIDDLE AGED;

ANTI-INFECTIVE AGENTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOXYCYCLINE; FEMALE; HUMANS; IVERMECTIN; MALE; METRONIDAZOLE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSACEA; TETRACYCLINE;

EID: 84944460887     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003262.pub5     Document Type: Review

References (329)

1. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology 2008;47(3):284-8. [PUBMED: 18289334]2865476
2. Alam M, Voravutinon N, Warycha M, Whiting D, Nodzenski M, Yoo S, et al. Comparative effectiveness of nonpurpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium:yttrium-aluminum-garnet laser for treatment of diffuse facial erythema: A double-blind randomized controlled trial. Journal of the American Academy of Dermatology 2013;69(3):438-43. [PUBMED: 23688651]2865478
3. Bamford JT, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Archives of Dermatology 1999;135(6):659-63. [UI: 99303186; PUBMED: 10376693]2865480
4. Bamford JT, Gessert CE, Haller IV, Kruger K. Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology 2009;129 Suppl 1:S41. [EMBASE: 70385883]2865483
5. Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology 2012;51(4):459-62. [PUBMED: 22435439]2865482
6. Barnhorst DA, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996;103(11):1880-3. [UI:97098344; PUBMED: 8942885]2865485
7. Benkali K, Leoni M, Rony F, Bouer R, Fernando A, Graeber M, et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. British Journal of Dermatology 2014;171(1):162-9. [PUBMED: 24506775]2865487
8. Berardesca E, Iorizzo M, Abril E, Guglielmini G, Caserini M, Palmieri R, et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology 2012;11(1):37-41. [PUBMED: 22360333]2865489
9. Beutner K, Calvarese B. A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology 2005;52(3 Suppl):P10. 2865491
10. Bitar A, Bourgouin J, Doré N, Dubuc R, Giroux JM, Madeleine-Landry EA. A double-blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation 1990;2(4):242-8. [EMBASE: 1991066113]2865493
11. Bjerke JR, Nyfors A, Austad J, Rajka G, Gjertsen BT, Haavelsrud O, et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal 1989;26(3):187-94. [EMBASE: 1989151247]2865495
12. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Dermato-Venerologica 1999;79(6):456-9. [UI: 20065819; PUBMED: 10598760]2865497
13. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Archives of Dermatology 1987;123(5):609-14. [UI: 8721097; PUBMED: 2953312]2865499
14. Blom I, Hornmark AM. Topical treatment with sulfur 10 per cent for rosacea. Acta Dermato-Venereologica 1984;64(4):358-9. [EMBASE: 1984179892]2865501
15. Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998;61(1):44-7. [UI:98127231; PUBMED: 9466083]2865503
16. Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of moderate to severe rosacea. International Journal of Dermatology 2004;43(5):381-7. [PUBMED: 15117375]2865505
17. Leyden LL, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/Clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis 2004;73(6 Suppl):11-7. [PUBMED: 15228129]2865506
18. Bribeche MR, Fedotov VP, Gladichev VV, Pukhalskaya DM, Kolitcheva NL. Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology 2015; Vol. 54, issue 4:481-7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098]2865508
19. Buendia-Bordera G, Ciscar E. Skin barrier function assessment by in vivo confocal microscopy and other non-invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post-laser serum. Lasers in Surgery and Medicine 2013;45 Suppl 25:43. [EMBASE: 71034059]2865510
20. Carmichael A, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment 1993;4(1 Suppl):S19-22. [EMBASE: 1993216511]2865512
21. Chang AL, Alora-Palli M, Lima XT, Chang TC, Cheng C, Chung CM, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology 2012;11(3):333-9. [PUBMED: 22395584]2865514
22. Dahl MV, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology 1998;134(6):679-83. [UI: 98307542; PUBMED: 9645635]2865516
23. Dahl MV, Jarratt MJ, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. Journal of the American Academy of Dermatology 2001;45(5):723-30. [PUBMED: 11606923]2865518
24. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology 2007;56(5):791-802. [PUBMED: 17367893]2865520
25. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology 2007;56(5):791-802. [PUBMED: 17367893]2865522
26. Del Rosso JQ, Caveney S. Comparison of anti-inflammatory dose doxycycline (30-mg immediate-release beads, 10 mg delayed-release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery 2012;31(1):A7-8. [EMBASE: 70706922]2865524
27. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology 2008;7(6):573-6. [PUBMED: 18561589]2865525
28. Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. Journal of Drugs in Dermatology 2010;9(6):607-13. [PUBMED: 20645521]2865527
29. Draelos ZD, Fuller BB. Efficacy of 1% 4-ethoxybenzaldehyde in reducing facial erythema. Dermatologic Surgery 2005;31(7 Pt 2):881-5. [PUBMED: 16029682]2865529
30. Draelos ZD, Green BA, Edison BL. An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. Journal of Cosmetic Dermatology 2006;5(1):23-9. [PUBMED: 17173568]2865531
31. Draelos Z, Erthel K, Schnicker M, Bacon R, Vickery S. Facial foundation with niacinamide and N-acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology 2009;60(3 Suppl 1):AB82. [EMBASE: 70142048]2865533
32. Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis; Cutaneous Medicine for the Practitioner 2013;92(6):306-17. [PUBMED: 24416747]2865535
33. Draelos Z, Hornby S, Walters RM, Appa Y. Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant-based cleansers. Journal of Cosmetic Dermatology 2013;12(4):314-21. [PUBMED: 24305430]2865537
34. Hornby S, Fowler J, Walters RM, Appa Y, Draelos Z. Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology 2013;68(4 Suppl 1):AB66. [EMBASE: 70997350]2865538
35. Dreno B, Dubertret L, Naeyaert JM, de la Brassine M, Marks R, Powell F, et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. Journal of the European Academy of Dermatology & Venereology 1998;11(2 Suppl):S272-3. 2865540
36. Elewski BE, Fleisher AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology 2003;139(11):1444-50. [PUBMED: 14623704]2865542
37. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Archives of Dermatology 1994;130(3):319-24. [UI: 94175557; PUBMED: 8129410]2865544
38. Espagne E, Guillaume JC, Archimbaud A, Baspeyras M, Boitier F, Bussière M, et al. Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0, 75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie 1993;120(2):129-33. [UI: 93370955; PUBMED: 8240534]2865546
39. Fabi S, Peterson J, Goldman M. Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery & Medicine 2011;43 Suppl 23:968-9. [EMBASE: 70640329]2865548
40. Fowler JFJr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology 2007;6(6):641-5. [PUBMED: 17668530]2865550
41. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology 2012;166(3):633-41. [PUBMED: 22050040]2865552
42. Meadows K, Jarratt M, Jones T, Pollack A, Stough D, Leoni M. A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology 2013;54 Suppl 2:48. [EMBASE: 71067783]2865553
43. Meadows K, Pollack A, Jarratt M, Jones T. A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology 2012;66(4 Suppl 1):AB41. [EMBASE: 70704014]2865554
44. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology 2012;166(3):633-41. [PUBMED: 22050040]2865556
45. Fowler J, Moore A, Meadows K, Grande K. Once-daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology 2012;66(4 Suppl 1):AB17. [EMBASE: 70703920]2865558
46. Fowler J, Moore A, Meadows K, Grande K, Steinhoff M, Leoni M. Once-daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology 2013;54 Suppl 2:48-9. [EMBASE: 71067784]2865557
47. Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of Drugs in Dermatology 2013;12(6):650-6. [PUBMED: 23839181]2865560
48. Fowler J, Jackson M, Steinhoff M, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea - Two randomized, double-blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology 2013;54 Suppl 2:49. [EMBASE: 71067785]2865561
49. Fowler JF, Moore A, Meadows K, Jackson M, Leoni M, Jarratt MT, at al. Efficacy and safety of once-daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double-blind, and vehicle-controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology 2013;68(4 Suppl 1):AB15. [EMBASE: 70997145]2865562
50. Jackson JM, Fowler J, Moore A, Jarratt M, Jones T, Meadows K, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology 2014;13(6):699-704. [PUBMED: 24918560]2865563
51. Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of Drugs in Dermatology 2013;12(6):650-6. [PUBMED: 23839181]2865565
52. Jackson JM, Fowler J, Moore A, Jarratt M, Jones T, Meadows K, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology 2014;13(6):699-704. [PUBMED: 24918560]2865566
53. Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline - and placebo-controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft 2010;8(7):505-15. [DOI: 10.1111/j.1610-0387.2010.07345.x; PUBMED: 20337772]2865568
54. Gollnick H, Matthies C, Von Der Werth R. Double-blind, double-dummy, randomized, placebo-controlled, five armed, multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology 2010;62(3 Suppl 1):AB41. [EMBASE: 70142682]2865569
55. Grosshans E, Michel C, Arcade B, Cribier B. Rilmenidine in rosacea: a double blind study versus placebo [Rilménidine dans la rosacée: étude en double insu contre placebo]. Annales de Dermatologie et Venereologie 1997;124(10):687-91. [UI: 98413298; PUBMED: 9740864]2865571
56. Guillet B, Rostain E, Powell F, Gimenez Camarasa C, Dahan E, Piérard, et al. Metronidazole 0.75% gel and lotion are both effective in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology 1999;12(2 Suppl):S145. 2865573
57. Huang YE, Li XL, Li TJ. Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology 2012;41(5):308-9. [EMBASE: 2012449799]2865575
58. Huang E, Di Nardo A, Gallo R, Caveney S, Gottschalk RW. Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. 2013 International Investigative Dermatology Meeting Edinburgh United Kingdom. Conference Start: 20130508 Conference End: 20130511. Journal of Investigative Dermatology 2013;133 Suppl 1:S181. [EMBASE: 71083535]2865577
59. Huang EY, Di Nardo A, Preson NJ, Gallo RL, Gottschalk RW. Multicenter, randomized, double-blind, placebo-controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40 mg modified release. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology 2014;70(5 Suppl 1):AB9. [EMBASE: 71390129]2865578
60. Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology 2013;12(3):292-8. [PUBMED: 23545911]2865580
61. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. Journal of the American Academy of Dermatology 1998;39(3):502-4. [UI: 98409174; PUBMED: 9738794]2865582
62. Karsai S, Roos S, Raulin C. Treatment of facial telangiectasia using a dual-wavelength laser system (595 and 1, 064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery 2008;34(5):702-8. [PUBMED: 18318728]2865584
63. Kendall J, Winkelman W. A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health 2014;17(3):A181-2. [EMBASE: 71488504]2865586
64. Kim TG, Roh HJ, Cho SB, Lee JH, Lee SJ, Oh SH. Enhancing effect of pretreatment with topical niacin in the treatment of rosacea-associated erythema by 585-nm pulsed dye laser in Koreans: A randomized, prospective, split-face trial. British Journal of Dermatology 2011; Vol. 38, issue 5:510-3. [DOI: 10.1111/j.1365-2133.2010.10174.x.; PUBMED: 21143465]2865588
65. Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clinical and Experimental Dermatology 2010;35(3):251-6. [PUBMED: 19594764]2865590
66. Koçak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology 2002;205(3):265-70. [PUBMED: 12399675]2865592
67. Koch R, Wilbrand G. Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea [P-011]. Journal of the European Academy of Dermatology and Venerology 1999;12(32 Suppl):S143-4. 2865594
68. Lebwohl MG, Medansky RS, Russo CL, Plott RT. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology 1995;3(5):183-5. 2865596
69. Leyden JJ. Efficacy of a novel rosacea treatment system: an investigator-blind, randomized, parallel-group study. Journal of Drugs in Dermatology 2011;10(10):1179-85. [PUBMED: 21968669]2865598
70. Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology 2014;13(6):685-8. [PUBMED: 24918558]2865600
71. Luger T, Peukert N, Rother M. A multicentre, randomized, placebo-controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug-free ultra-deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology 2015; Vol. 29, issue 2:283-90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379]2865602
72. Lupin M. Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU-V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology 2014;70(5 Suppl 1):AB43. [EMBASE: 71390263]2865604
73. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology 1999;40(6 Pt 1):961-5. [UI: 99292050; PUBMED: 10365928]2865606
74. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet 1971;2(7733):1049-52. [UI: 72022755; PUBMED: 4106909]2865608
75. Monk BE, Logan RA, Cook J, White JE, Mason RBS. Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment 1991;2(3):91-3. [EMBASE: 1991353230]2865610
76. Montes LF, Cordero AA, Kriner J, Loder J, Flanagan AD. Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis 1983;32(2):185-90. [PUBMED: 6225627]2865612
77. Mostafa FF, El Harras MA, Gomaa SM, Al Mokadem S, Nassar AA, Abdel Gawad EH. Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology 2009;23(1):22-8. [PUBMED: 18705632]2865614
78. NCT00249782. A phase II, randomized, partial-blind, parallel-group, active- and vehicle-controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). 2865616
79. NCT01426269. Evaluation of relapse, efficacy and safety of long-term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). 2865618
80. NCT01449591. A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). 2865620
81. NCT01885000. Patient-Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). 2865622
82. Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery 2009;35(6):920-8. [PUBMED: 19397667]2865624
83. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. British Journal of Dermatology 1983;108(3):327-32. [PUBMED: 6219689]2865626
84. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology 1983;109(1):63-5. [UI: 83231308; PUBMED: 6222756]2865628
85. Nymann P, Hedelund L, Haedersdal M. Long-pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology 2010;24(2):143-6. [PUBMED: 20205349]2865630
86. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976;1(7971):1211-2. [UI: 76195079; PUBMED: 58258]2865632
87. Rehmus W, Kim J. A double-blind, placebo-controlled study of a natural anti-inflammatory for treatment of rosacea. Journal of the American Academy of Dermatology 2006;54(3 Suppl):AB64. 2865634
88. Rigopoulos D, Kalogeromitros D, Gregoriou S, Pacouret JM, Koch C, Fisher N, et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology 2005;19(5):564-8. [PUBMED: 16164709]2865636
89. Rodríguez Acar M, Medina Hernández E. A comparative, double-blind study about efficacy and safety of crotamiton vs benzyl benzoate in the treatment of rosacea with demodecidosis [Estudio doble ciego, comparativo, sobre la eficacia y seguridad del crotamitón versus benzoato de bencilo en el tratamiento de la rosácea con demodecidosis]. Dermatología Revista Mexicana 2003;47(3):126-30. [EMBASE: 2007502703]2865638
90. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. British Journal of Dermatology 1980;102(4):443-5. [PUBMED: 6446314]2865640
91. Salem DA, El-Shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases 2013;17(5):343-7. [PUBMED: 23294870]2865642
92. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology 2005;53(5):791-7. [PUBMED: 16243127]2865644
93. Sanchez JL, Somolinos A, Webster G, Bradshaw M. Combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology 2004;50(3):48. 2865645
94. Sauder DN, Miller R, Gratton D, Danby W, Griffiths C, Philips SB. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. Journal of Dermatological Treatment 1997;8(2):79-85. [EMBASE: 1997242784]2865647
95. Schachter D, Schachter RK, Long B, Shiffman N, Lester R, Miller S, et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation 1991;3(4):220-4. [EMBASE: 1991314872]2865649
96. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy 2009;26(6):651-9. [PUBMED: 19551353]2865651
97. Seité S, Benech F, Berdah S, Bayer M, Veyrat S, Segot E, et al. Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology 2013;12(8):920-4. [EMBASE: 2013521246]2865653
98. Sharquie KE, Najim RA, Al-Salman HN. Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. International Journal of Dermatology 2006;45(7):857-61. [PUBMED: 16863527]2865655
99. Sneddon IB. A clinical trial of tetracycline in rosacea. British Journal of Dermatology 1966;78(12):649-52. [PUBMED: 4224811]2865657
100. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of Drugs in Dermatology 2014;13(3):316-23. [PUBMED: 24595578]2865659
101. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of Drugs in Dermatology 2014;13(3):316-23. [PUBMED: 24595578]2865661
102. Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. British Journal of Dermatology 2015; Vol. 172, issue 4:1103-10. [PUBMED: 25228137]2865663
103. Tan JKL, Girard C, Krol A, Murray HE, Papp KA, Poulin Y, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. Journal of Cutaneous Medicine and Surgery 2002;6(6):529-34. [PUBMED: 12001006]2865665
104. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle-controlled, randomized phase III studies. Journal of the American Academy of Dermatology 2003;48(6):836-45. [PUBMED: 12789172]2865667
105. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle-controlled, randomized phase III studies. Journal of the American Academy of Dermatology 2003;48(6):836-45. [PUBMED: 12789172]2865669
106. Thiboutot D. Efficacy and safety of subantimicrobial-dose doxycycline for the treatment of rosacea. Journal of the American Academy of Dermatology 2005;52(3 Suppl 1):17. 2865671
107. Thiboutot DM, Fleisher AB, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology 2008;7(6):541-6. [PUBMED: 18561584 ]2865673
108. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich PH. A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology 2009;8(7):639-48. [PUBMED: 19588640]2865675
109. Tirnaksiz F, Kayiş A, Çelebi N, Adişen E, Erel A. Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical & Pharmaceutical Bulletin 2012;60(5):583-92. [PUBMED: 22689395]2865677
110. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005;75(6):357-63. [PUBMED: 16047874]2865679
111. Two AM, Hata TR, Nakatsuji T, Coda AB, Kotol PF, Wu W, et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology 2014;134(4):1143-5. [PUBMED: 24213369]2865681
112. Utaş S, Ünver Ü. Treatment of rosacea with ketoconazole. Journal of the European Academy of Dermatology and Venereology 1997;8(1):69-70. [EMBASE: 1997013740]2865683
113. Van Landuyt H, Joubert-Lequain I, Humbert P, Lucas A, Drobacheff C, Mercier M, et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results) [Traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie 1997;124(10):729. [PUBMED: 9740876]2865685
114. Veien NK, Christiansen JV, Hjorth N, Schmidt H. Topical metronidazole in the treatment of rosacea. Cutis 1986;38:209-10. [PUBMED: 2945705]2865687
115. Verea Hernando M, Margusino Framiñán L, Seco Vilariño C, Feal Cortizas B, Cuña Estévez B. Comparative study of topical erythromycin and topical metronidazole in the treatment of rosacea [Estudio comparativo entre eritromicina tópica y metronidazol tópico en el tratamiento de la rosácea]. Farmacia Clinica 1992;9(6):472-9. [EMBASE: 1992280716]2865689
116. Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. British Journal of Dermatology 2007;156(4):728-32. [PUBMED: 17493072]2865691
117. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. Journal of the American Academy of Dermatology 1989;20(2 Pt 1):202-5. [PUBMED: 2521641]2865693
118. De Witt S, Wilkin JK. Double blind, parallel study of efficacy and safety of clindamycin lotion in the treatment of rosacea. Clinical Pharmacology and Therapeutics 1987;41(2):176. 2865695
119. Wilkin JK, De Witt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. International Journal of Dermatology 1993;32(1):65-7. [UI: 93146772; PUBMED: 8425809]2865696
120. Wittpenn JR, Schechter B. Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology & Visual Science 2005;46:E-Abstract 2846. 2865698
121. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006;77(4 Suppl):3-11. [PUBMED: 16706244]2865700
122. Yoo J, Marmur E, Frankel AL, Chaarani J, Turner R, Singer G. Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery & Medicine 2011;43 Suppl 23:918. 2865702
123. Aitken G. Acne rosacea: Efficacy of a metronidazole cream [Efficacité d' une crème au métronidazole]. Presse Médicale 1983;12(23):1490-1. [EMBASE: 6222348]2865704
124. Aizawa H, Niimura M. Oral spironolactone therapy in male patients with rosacea. Journal of Dermatology 1992;19(5):293-7. [EMBASE: 1992221634]2865706
125. Altinyazar HC, Koca R, Tekin NS, Eştürk E. Adalapene vs. metronidazole gel for the treatment of rosacea. International Journal of Dermatology 2005;44(3):252-5. [MEDLINE: 15807740]2865708
126. Aronson IK, Rumsfield JA, West DP, Alexander J, Fisher JH, Paloucek FP. Evaluation of topical metronidazole gel in acne rosacea. Drug Intelligence & Clinical Pharmacy 1987;21(4):346-51. [MEDLINE: 2952478]2865710
127. Bakar B. Acne rosacea: an open comparative trial of azithromycin versus oxytetracycline therapy: study of 50 patients [P139]. Journal of the American Academy of Dermatology 2006;54(3 Suppl 1):AB24. 2865712
128. Bang Soon K, Seung Ho Ch, Mi Kyung Ch. Treatment of rosacea with photopnematic therapy [212]. Lasers in Surgery & Medicine 2007;39(19 Suppl):65. 2865714
129. Bartholomew RS, Reid BJ, Cheesbrough MJ, MacDonald M, Galloway NR. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. British Journal of Ophthalmology 1982;66(6):386-8. [MEDLINE: 6211188]2865716
130. Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. Journal of Cosmetic Dermatology 2008;7(1):8-14. [MEDLINE: 18254805]2865718
131. Beridze LR, Mikaia LA, Bakuridze AD. Perolen cream for therapy of rosacea. Georgian Medical News 2005;120(3):55-7. [MEDLINE: 15855701]2865720
132. Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. British Journal of Dermatology 1982;107(1):59-61. [EMBASE: 1982170962]2865722
133. Bjerke JR. Rosacea. Clinical features and treatment [Rosacea. Klinikk og behandling]. Tidsskrift for den Norske Laegeforening 1989;109(23):2295-7. 2865724
134. Bukvic-Mokos Z, Basta-Juzbasic A, Barasic-Drusko V. Treatment of Helicobacter pylori infection in the management of rosacea. Acta Dermatovenerologica Croatica 1998;6(4):185-8. [EMBASE: 1999113348]2865726
135. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. British Journal of Dermatology 2005;152(2):396-9. [PUBMED: 15727676]2865728
136. Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis 2007;79(4):317-21. [PUBMED: 17500380]2865730
137. Cunliffe WJ, Dodman B, Binner JG. Clonidine and facial flushing in rosacea. British Medical Journal 1977;1(6053):105. [EMBASE: 0978017820]2865732
138. Del Rosso JQ. The use of topical azelaic acid 15% gel or metronidazole 0.75% gel for the treatment of rosacea: Evaluation of a single-site comparative trial subset. Journal of the American Academy of Dermatology 2004;50(3):174. 2865734
139. Dereli T, Inanir I, Kilinç I, Gençoğlan G. Azithromycin in the treatment of papulopustular rosacea. The Journal of Dermatology 2005;32(11):926-8. [MEDLINE: 16361757]2865736
140. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis 2005;76(2):135-41. [PUBMED: 16209160]2865738
141. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Archives of Dermatology 1998;134(7):884-5. [EMBASE: 1998253772]2865740
142. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Archives of Dermatology 2004;140(4):489-90. [EMBASE: 2004163208]2865742
143. Fleischer A, Suephy C. The face and mind evaluation study: An examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. Journal of Drugs in Dermatology 2005;4(5):585-90. [MEDLINE: 16167417]2865744
144. Freeman SA, Moon SD, Spencer JM. Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial. Journal of Drugs in Dermatology 2012;11(12):1410-4. [PUBMED: 23377509]2865746
145. Frigerio G, Mazzoni P, Ferrari V. Dimensions of the sample and power of clinical experimentation in a study of antibiotic therapy [Dimensioni del camione e potenza dell' esperimento clinico in una ricerca di terapia antibiotica]. Bollettino Chimico Farmaceutico 1969;108(8):506-14. 2865748
146. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. American Journal of Ophthalmology 1993;116(1):88-92. [UI: 93318953; PUBMED: 8328549]2865750
147. Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. Journal of the European Academy of Dermatology and Venereology 2008;23(2):239-40. [PUBMED: 18498336]2865752
148. Gedik GK, Karaduman A, Sivri B, Caner B. Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms?. Journal of the European Academy of Dermatology and Venereology 2005;19(3):398-9. [PUBMED: 15857486]2865754
149. Go MJ, Wuite J. Comparative study of triamcinolone acetonide and hydrocortisone 17-butyrate in rosacea with special regard to rebound phenomenon. Dermatologica 1976;152(1 Suppl):239-46. [PUBMED: 133841]2865756
150. Goldsmith MF. New topical therapy for acne rosacea offers conspicuous improvement, no systemic effects. JAMA 1989;261(14):2014-5. [PUBMED: 2522563]2865758
151. Hofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clinical & Experimental Dermatology 2004;29(2):204-5. [PUBMED: 14987287]2865760
152. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. Acne and related disorders - Proceedings of an international symposium. London, 1988:301-5. 2865762
153. Jackson M. Combined effect of anti-inflammatory dose doxycycline and azelaic acid gel 15% in the treatment of rosacea. Journal of the American Academy of Dermatology 2007;56(2 Suppl 2):AB19. 2865764
154. Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. Journal of the European Academy of Dermatology and Venereology 2008;22(6):729-34. [PUBMED: 18328059]2865766
155. Koçak-Altintas AG, Koçak-Midillioglu I, Gul U, Bilezickci B, Isiksacan O, Duman S. Effects of topical metranidazole in ocular rosacea. Annals of Ophthalmology 2005;37(2):77-84. [EMBASE: 2005358977]2865768
156. Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. Journal of Dermatological Treatment 2007;18(3):158-62. [PUBMED: 17538804]2865770
157. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: An 8-week split-face clinical trial. British Journal of Dermatology 2008;158(5):1069-76. [PUBMED: 18363758]2865772
158. Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: A systematic review of randomized controlled trials. Archives of Dermatology 2006;142(8):1047-52. [PUBMED: 16924055]2865774
159. Loo WJ, Ayyalaraju A, Chawla M, Finlay AY, Coles EC, Marks R. Ivermectin cream in rosacea: Comparison with metronidazole gel. British Journal of Dermatology 2004;151(68):61. 2865776
160. Määttä M, Kari O, Tervahartiala T, Wahlgren J, Peltonen S, Kari M, et al. Elevated expression and activation of matrix metalloproteinase 8 in tear fluid in atopic blepharoconjunctivitis. Cornea 2008;27(3):297-301. [PUBMED: 18362656 ]2865778
161. Maxwell EL, Ellis DA, Manis H. Acne rosacea: Effectiveness of 532 nm laser on the cosmetic appearance of the skin. Journal of Otolaryngology - Head & Neck Surgery 2010;39(3):292-6. [PUBMED: 20470675]2865780
162. Meekin TO, Lertzman BH, Hahn HH, Arcara K. Randomized study of intense pulsed light and pulsed dye laser in the treatment of facial telangiectasia. Journal of the American Academy of Dermatology 2008;40 Suppl 20:25. 2865782
163. Mraz S, Beutner K. The combination of metronidazole gel and sodium sulfacetamide cleanser is efficacious and well-tolerated by rosacea patients [P114]. Journal of the American Academy of Dermatology 2008;58(2 Suppl 2):AB14. 2865784
164. Nasir MA. Treatment of rosacea with tetracycline and metronidazole - A comparative study. Journal of the Pakistan Medical Association 1985;35(5):148-9. [PUBMED: 3160868]2865786
165. Nielsen PG. The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream. British Journal of Dermatology 1983;109(1):122. [PUBMED: 6222753]2865788
166. Ortiz A, Elkeeb L, Truitt A, Hindiyeh R, Aquino L, Tran M, Weinstein G. Topical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea. Journal of Drugs in Dermatology 2009;8(5):459-62. [PUBMED: 19537369]2865790
167. Oztürkcan S, Ermertcan AT, Sahin MT, Afşar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. Journal of Dermatology 2004;31(8):610-7. [PUBMED: 15492433]2865792
168. Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, et al. Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication. Clinical Gastroenterology and Hepatology 2008;6(7):759-64. [PUBMED: 18456568 ]2865794
169. Ruggero C, Barbareschi M, Veraldi S. Pulse-therapy with azithromycin in acne rosacea and peri-oral dermatitis: an open study. Journal of the American Academy of Dermatology 2005;52(3 Suppl 1):P4. 2865796
170. Sainthillier J-M, Mac-Mary S, Creidi P, Msika P, Chadoutaud B, Humbert P. Comparative evaluation by colorimetry and videocapillaroscopy of the efficacy of a cream composed of peptide of lupin and soya isoflavones on erythrocouperose [Évaluation comparative par colorimétrie et vidéocapillaroscopie de l'efficacité d'une crème composée de peptide de lupin et d'isoflavones de soja sur l'érythrocouperose]. Nouvelles Dermatologiques 2005;24(2):99-104. [EMBASE: 2005110281]2865798
171. Seal DV, Wright P, Ficker L, Hagan K, Troski M, Menday P. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. British Journal of Ophthalmology 1995;79(1):42-5. [UI: 95186449; PUBMED: 7880791]2865800
172. Sehgal VN, Sharma S, Sardana K. Rosacea/acne rosacea: Efficacy of combination therapy of azithromycin and topical 0.1% tacrolimus ointment. Journal of the European Academy of Dermatology and Venereology 2008;22(11):1366-8. [PUBMED: 18435734]2865802
173. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Archives of Dermatology 2007;143(11):1369-71. [PUBMED: 18025359]2865804
174. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis 1995;56(3):177-9. [UI 96098375; PUBMED: 8565604]2865806
175. Stoudemayer M, Zhen Y, Stoudemayer T, Kligman A. Evaluation of a topical treatment containing 8% sulfur and 2% resorcinol in the treatment of centrofacial rosacea. Journal of the American Academy of Dermatology 2006;54(3 Suppl):AB17. 2865808
176. Tierney E, Hanke CW. Randomized controlled trial: Comparative efficacy for the treatment of facial telangiectasias with 532 nm versus 940 nm diode laser. Lasers in Surgery & Medicine 2009;41(8):555-62. [PUBMED: 19746429]2865810
177. Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. Journal of the European Academy of Dermatology and Venereology 2009;23(2):200-1. [PUBMED: 18452529]2865812
178. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. International Journal of Dermatology 1997;36(12):942-6. [PUBMED: 9466207]2865814
179. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. Journal of Drugs in Dermatology 2009;8(3):299-304. [PUBMED: 19271381]2865816
180. Uebelhoer NS, Bogle MA, Stewart B, Arndt KA, Dover JS. A split-face comparison study of pulsed 532-nm KTP laser and 595-nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema. Dermatologic Surgery 2007;33(4):441-8. [PUBMED: 17430378]2865818
181. Veien NK. Metronidazole cream for the local treatment of rosacea [Metronidazolcreme til lokalbehandling af rosacea]. Ugeskrift for Laeger 1988;150(6):381-2. [EMBASE: 2968013]2865820
182. Veraldi S, Scarabelli G, Rizzitelli G, Caputo R. Treatment of rosacea fulminans with isotretinoin and topical alclometasone dipropionate. European Journal of Dermatology 1996;6(2):94-6. [EMBASE: 1996085850]2865822
183. Viera MH, Perez OA, Berman B. Incyclinide. Dual MMP-2/MMP-9 inhibitor treatment of acne treatment of rosacea. Drugs of the Future 2007;32(3):209-14. [DOI: 10.1358/dof.2007.032.03.1083308; EMBASE: 2007289664]2865824
184. Yu TG, Zheng YZ, Zhu JT, Guo W. Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. Chinese Journal of Integrative Medicine 2006;12(4):277-80. [PUBMED: 17361524]2865826
185. ACTRN12614000004662. A single-blind randomised controlled trial of topical Kanuka honey for the treatment of rosacea. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365179 (accessed 21 July 2014). 2865828
186. IRCT2014030416837N1. Effects of permethrin 5% topical gel in comparison with placebo on Demodex density in rosacea patients: a double-blind, randomized clinical trial. www.irct.ir/searchresult.php?keyword=&id=16837&number=1&prt=6008&total=10&m=1 (accessed 23 September 2014). 2865830
187. NCT00560703. Efficacy and safety of COL-101 for the treatment of blepharitis in patients with facial rosacea. clinicaltrials.gov/ct2/show/NCT00560703 (accessed 16 July 2014). 2865832
188. NCT00617903. A 12-week exploratory, multicenter, double-blind, vehicle-controlled study to investigate the efficacy and safety of topical azelaic acid 15% foam twice daily in patients with papulopustular rosacea. clinicaltrials.gov/ct2/show/NCT00617903 (accessed 18 July 2014). 2865834
189. NCT00882531. Evaluation of the efficacy of isotretinoin versus placebo in terms of response rate among patients presenting papular-pustular rosacea resistant to standard therapy. clinicaltrials.gov/ct2/show/NCT00882531 (accessed 18 July 2014). 2865836
190. NCT01125930. Investigation of the topical retinoid, Atralin gel 0.05% for the treatment of erythematotelangiectatic rosacea. clinicaltrials.gov/ct2/show/NCT01125930 (accessed 19 July 2014). 2865838
191. NCT01451619. A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the pharmacodynamics of MK-0524 in subjects with moderate to severe erythematotelangiectatic rosacea. (protocol No. 155). clinicaltrials.gov/show/NCT01451619 (accessed 19 July 2014). 2865840
192. NCT01579084. Safety and tolerability of AGN-199201 in patients with erythema associated with rosacea. clinicaltrials.gov/show/NCT01579084 (accessed 21 July 2014). 2865842
193. NCT01614743. A double-blinded, randomized placebo controlled pilot study comparing the efficacy and safety of Incobotulinumtoxin A versus saline injections to the cheek region in patients with rosacea. clinicaltrials.gov/show/NCT01614743 (accessed 19 July 2014). 2865844
194. NCT01631656. Combination Finacea gel and vascular Nd:Yag laser therapy for mild to moderate rosacea. clinicaltrials.gov/show/NCT01631656 (accessed 20 July 2014). 2865846
195. NCT01735201. AGN-199201 for the treatment of erythema with rosacea. clinicaltrials.gov/show/NCT01735201 (accessed 21 July 2014). 2865848
196. NCT01740934. An eight-week, multi-site, double-blind, randomized, vehicle-controlled, parallel-group trial to evaluate the safety, tolerability, and effects of Anatabloc® crème in subjects with rosacea followed by an open-label extension. clinicaltrials.gov/show/NCT01740934 (accessed 20 July 2014). 2865850
197. EUCTR2006-001999-20-HU. Assessment of the efficacy and safety of three concentration:1%, 0.3%, 0.1% of CD5024 cream once daily and CD5024 1% cream twice daily, versus its vehicle and versus metronidazole cream (Rozex®) in patients with papulopustular rosacea over 12 weeks. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865852
198. EUCTR2006-003707-40-DE. Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865854
199. EUCTR2006-007029-29-EE. Non inferiority study of metronidazole 0.75% cream versus reference therapy in the local treatment of papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23-9-2014). 2865856
200. EUCTR2008-003854-13-FR. An investigator blind parallel group vehicle control study comparing the efficacy ad safety of CD 5024 1% cream with metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865858
201. EUCTR2009-013111-35-DE. Effect of CD08514 versus placebo, in patients presenting with type 1 rosacea, over an 8-week treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865860
202. EUCTR2010-018319-13-DE. A double-blind, vehicle controlled, parallel group study assessing the activity of CD5024 1% cream in subjects with papulopustular rosacea over 12 weeks treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865862
203. EUCTR2010-021150-19-NL. Doxycycline versus minocycline in the treatment of rosacea: a randomised controlled trial. - DoMino-study. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865864
204. EUCTR2010-023566-43-DE. No English title [Multizentrische, randomisierte, doppelblinde, kontrollierte Phase III-Studie zur Behandlung der papulopustulären Rosazea mit Permethrin Creme 5 % (InfectoScab®) versus Permethrin Creme 2, 5 % versus Metronidazol Creme 0, 75 % (Rozex®) - Papulopustuläre Rosazea-Behandlung mit Permethrin Creme versus Metronidazol Creme]. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865866
205. EUCTR2011-002057-65-DE. Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865868
206. EUCTR2011-002058-30-DE. Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865870
207. EUCTR2011-004791-11-CZ. Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36-week extension period. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865872
208. EUCTR2012-001044-22-SE. A multicenter, randomized, double-blind, vehicle-controlled, parallel group study to demonstrate the efficacy and assess the safety of CD07805/47 gel 0.5%applied topically once daily in subjects with moderate to severe facial erythema of rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865874
209. EUCTR2013-005083-26-DE. Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea - Effect of CD07805/47 gel in rosacea flushing. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865876
210. IRCT2014010516079N1. Comparison of dapsone 5% topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865878
211. JPRN-UMIN000008315. Clinical trial for development of topical rapamycin treatment for rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). 2865880
212. NCT00041977. A multicenter, randomized, double-blind, placebo-controlled, clinical trial to determine the effects of doxycycline hyclate 20 mg tablets [Periostat(R)] administered twice daily for the treatment of acne rosacea. clinicaltrials.gov/ct2/show/NCT00041977 (accessed 21 July 2014). 2865882
213. NCT00436527. MetroGel 1% hydration study: a kinetic regression study. clinicaltrials.gov/show/NCT00436527 (accessed 19 July 2014). 2865884
214. NCT00495313. Determine the effects of COL-101 administered once daily with metronidazole topical gel, 1% versus doxycycline hyclate 100 mg administered once daily with metronidazole topical gel, 1% in patients with moderate to severe rosacea. clinicaltrials.gov/ct2/show/NCT00495313 (accessed 16 July 2014). 2865886
215. NCT00621218. A pilot study to compare tretinoin gel, 0.05% to tretinoin gel vehicle when dosed once or twice daily in female subjects with classical rosacea. clinicaltrials.gov/ct2/show/NCT00621218 (accessed 18 July 2014). 2865888
216. NCT00667173. A phase 2, multi-center, evaluator-blind, randomized, vehicle-controlled clinical study to assess the safety and efficacy of IDP-115 in the treatment of rosacea. clinicaltrials.gov/ct2/show/NCT00667173 (accessed 18 July 2014). 2865890
217. NCT00697541. A phase II, single-center, two-way crossover relative systemic bioavailability study of Col-118 administered topically as a 0.18 % facial gel and brimonidine ophthalmic solution 0.2% administered to the eye in subjects with moderate to severe erythematous rosacea. clinicaltrials.gov/ct2/show/NCT00697541 (accessed 18 July 2014). 2865892
218. NCT01016782. Multi-center, double-blind, randomized, vehicle-controlled, parallel group study of 0444 gel. clinicaltrials.gov/ct2/show/NCT01016782 (accessed 19 July 2014). 2865894
219. NCT01134991. Pilot, randomized, double blind, placebo controlled, parallel group, dose range finding study, to evaluate the tolerability and safety of FXFM244 antibiotic foam and to monitor its clinical effect in moderate to severe rosacea patients. clinicaltrials.gov/ct2/show/NCT01134991 (accessed 19 July 2014). 2865896
220. NCT01186068. A randomized, double-blind, vehicle-controlled, parallel-group study of the dose-response profile of V-101 cream in subjects with erythematous rosacea. clinicaltrials.gov/ct2/show/NCT01186068 (accessed 19 July 2014). 2865898
221. NCT01257919. Investigator-blinded, randomized, cross-over, multiple dose phase I study on safety and pharmacokinetics of topically applied azelaic acid foam, 15% compared to azelaic acid gel, 15% in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01257919 (accessed 19 July 2014). 2865900
222. NCT01308619. A multicenter, randomized, double-blind, placebo-controlled evaluation of rosacea-related inflammatory biochemical markers in the skin of adults with papulopustular rosacea treated with daily doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) capsules. clinicaltrials.gov/show/NCT01308619 (accessed 19 July 2014). 2865902
223. NCT01513863. A randomized, double-blind, placebo controlled, parallel design, multi-site clinical study to compare the bioequivalence of two metronidazole 1% topical gel formulations in patients with moderate to severe rosacea. clinicaltrials.gov/show/NCT01513863 (accessed 19 July 2014). 2865904
224. NCT01555463. A randomized, double-blind, vehicle-controlled, multicenter, parallel-group clinical trial to assess the safety and efficacy of azelaic acid foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01555463 (accessed 20 Juy 2014). 2865906
225. NCT01659853. A multicenter, randomized, controlled, double-masked, crossover design study to compare efficacy and assess safety of CD07805/47 gel 0.5% applied once daily vs azelaic acid gel 15% applied twice daily in subjects with erythema of rosacea. clinicaltrials.gov/show/NCT01659853 (accessed 20 July 2014). 2865908
226. NCT01784133. A phase 2, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of three once-daily CLS001 topical gels versus vehicle administered for 12 weeks to subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01784133 (accessed 20 July 2014). 2865910
227. NCT01828177. A multicenter randomized evaluator-blinded vehicle-controlled parallel group evaluation of twice daily PDI-320 in comparison to its monads in adults with rosacea. clinicaltrials.gov/show/NCT01828177 (accessed 20 July 2014). 2865912
228. NCT01917539. Efficacy of Pulsed Light Therapy for Meibomian gland dysfunction and dry eye syndrome. clinicaltrials.gov/show/NCT01917539 (accessed 21 July 2014). 2865914
229. NCT01933464. An analysis of the effect of topical cromolyn sodium on rosacea-associated erythema. clinicaltrials.gov/show/NCT01933464 (accessed 20 July 2014). 2865916
230. NCT01993446. A randomized, double-blind, vehicle controlled study of the safety and efficacy of topical DRM02 in subjects with rosacea. clinicaltrials.gov/show/NCT01993446 (accessed 20 July 2014). 2865918
231. NCT02036229. A randomised, double blind, placebo controlled, half-face study to evaluate the effect of topical ivermectin cream 0.5% on demodicidosis. clinicaltrials.gov/ct2/show/NCT02036229 (accessed 20 July 2014). 2865920
232. NCT02052999. An open label pilot study to evaluate the efficacy of PAC-14028 in the treatment of erythematotelangiectatic rosacea and papulopustular rosacea. clinicaltrials.gov/show/NCT02052999 (accessed 20 July 2014). 2865922
233. NCT02075671. Photodynamic therapy for papulopustular rosacea. clinicaltrials.gov/show/NCT02075671 (accessed 20 July 2014). 2865924
234. NCT02120924. A multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to evaluate the safety and clinical equivalence of a generic azelaic acid gel, 15% and the reference listed Finacea® (azelaic acid) gel, 15% in patients with moderate facial rosacea. clinicaltrials.gov/show/NCT02120924 (accessed 20 July 2014). 2865926
235. NCT02132117. Safety and efficacy of AGN-199201 in patients with persistent erythema associated with rosacea. clinicaltrials.gov/show/NCT02132117 (website accessed 20 July 2014). 2865928
236. NCT02144181. Evaluation of the safety and efficacy of the Ulthera® System for the treatment of signs and symptoms of erythematotelangiectatic rosacea. clinicaltrials.gov/show/NCT02144181 (accessed 20 July 2014). 2865930
237. NCT02147691. Finacea 15% and brimonidine 0.33% gel in the treatment of rosacea - a pilot study. clinicaltrials.gov/show/NCT02147691 (accessed 20 July 2014). 2865932
238. NCT02204254. Prospective, open label, randomized study comparing bipolar radiofrequency potentiated by infrared light to doxycycline in patient with papulopustular rosacea. clinicaltrials.gov/show/NCT02204254 (accessed 23 September 2014). 2865934
239. Abram K, Silm H, Maaroos HI, Oona M. Subjective disease perception and symptoms of depression in relation to healthcare-seeking behaviour in patients with rosacea. Acta Dermato-Venereologica 2009;89(5):488-91. [PUBMED: 19734974]
240. Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. British Journal of Dermatology 2010;163(4):719-25. [PUBMED: 20545683]
241. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. American Journal of Clinical Dermatology 2010;11(2):79-87. [PUBMED: 20141228]
242. Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. International Journal of Dermatology 2004;43(2):151-4. [MEDLINE: 15125511]
243. Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. Journal of the European Academy of Dermatology and Venereology 2009;23(5):544-9. [PUBMED: 19250326]
244. Baldwin HE. Oral therapy for rosacea. Journal of Drugs in Dermatology 2006;5(1):16-21. [PUBMED: 16468287]
245. Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis 2010;86(5 Suppl):26-36. [PUBMED: 21229828]
246. Bamford JTM, Gessert CE, Renier CM. Measurement of the severity of rosacea. Journal of the American Academy of Dermatology 2004;51(5):697-703. [EMBASE: 2004494171]
247. Bamford JT, Gessert CE, Renier CM, Jackson MM, Laabs SB, Dahl MV, et al. Childhood stye and adult rosacea. Journal of the American Academy of Dermatology 2006;55(6):951-5. [PUBMED: 17097390]
248. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. British Journal of Dermatology 2008;159(5):997-1035. [PUBMED: 18795920]
249. Berg M, Lidén S. An epidemiological study of rosacea. Acta Dermato-Venereologica 1989;69(5):419-23. [PUBMED: 2572109]
250. Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers in Surgery & Medicine 2008;40(4):233-9. [PUBMED: 18412227]
251. Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item 2013. www.thecochranelibrary.com/details/editorial/5655431/Why-the-Cochrane-risk-of-bias-tool-should-include-funding-source-as-a-standard-item.html (accessed 14 January 2015).
252. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. Journal of Drugs in Dermatology 2012;11(7):838-44. [PUBMED: 22777226]
253. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003;2(4):234-45. [PUBMED: 14673277]
254. Bikowski JB, Goldman MP. Rosacea: Where are we now?. Journal of Drugs in Dermatology 2004;3(3):251-61. [PUBMED: 15176158]
255. Bikowski J. Demystifying anti-inflammatory dose antibiotics for management of rosacea. Practical Dermatology 2007;April:22-4.
256. Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne rosacea. Journal of Drugs in Dermatology 2006;5(1):35-9. [PUBMED: 16468290]
257. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. Journal of Investigative Dermatology 1996;107(5):707-13. [PUBMED: 8875954]
258. Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. Journal of the European Academy of Dermatology and Venereology 2007;21(4):484-90. [PUBMED: 17373975]
259. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005;4(3):147-50. [PUBMED: 15891250]
260. Cresce ND, Davis SA, Huang WW, Feldman SR. The quality of life impact of acne and rosacea compared to other major medical conditions. Journal of Drugs in Dermatology 2014;13(6):692-7. [PUBMED: 24918559]
261. Culp B, Scheinfeld N. Rosacea: A Review. P & T 2009;34(1):38-45. [PUBMED: 19562004]
262. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. Journal of Clinical and Aesthetic Dermatology 2012;5(3):16-25. [PUBMED: 22468176]
263. Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013;91(3 Suppl):1-8. [PUBMED: 23833998]
264. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013;92(6):277-84. [PUBMED: 24416742]
265. Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?. Journal of the American Academy of Dermatology 2013;69(6 Suppl 1):S44-56. [PUBMED: 24229637]
266. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 3: A status report on systemic therapies. Cutis 2014;93(1):18-28. [PUBMED: 24505581]
267. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis 2014;93(3):134-8. [PUBMED: 24738094]
268. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563 ]
269. El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009992.pub2]
270. Elewski BE. Results of a national rosacea patient survey: Common issues that concern rosacea sufferers. Journal of Drugs in Dermatology 2009;8(2):120-3. [PUBMED: 19213226]
271. Elewski BE, Draelos Z, Dréno B, Jansen T, Layton A, Picardo M. Rosacea - global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology 2011;25(2):188-200. [PUBMED: 20586834]
272. Feldman SR, Huang WW, Huynh TT. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. Journal of Managed Care Pharmacy 2014;20(6):623-9. [PUBMED: 24856600]
273. Forton F. Standardized skin surface biopsy: method to estimate the Demodex folliculorum density, not to study the Demodex folliculorum prevalence. Journal of the European Academy of Dermatology and Venereology 2007;21(9):1301-2. [PUBMED: 17894752]
274. Forton FM. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. Journal of the European Academy of Dermatology and Venereology 2012;26(1):19-28. [PUBMED: 22017468]
275. Gessert CE, Bamford JT. Measuring the severity of rosacea: A review. International Journal of Dermatology 2003;42(6):444-8. [PUBMED: 12786870]
276. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [PUBMED: 18436948]
277. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
278. Jansen T, Plewig G. Rosacea: Classification and treatment. Journal of the Royal Society of Medicine 1997;90(3):144-50. [PUBMED: 9135612]
279. Kawana S, Ochiai H, Tachihara R. Objective evaluation of the effect of intense pulsed light on rosacea and solar lentigines by spectrophotometric analysis of skin color. Dermatologic Surgery 2007;33(4):449-54. [PUBMED: 17430379]
280. Kini SP, Nicholson K, DeLong LK, Dannemann T, Estaris J, Foster J, et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. Journal of the American Academy of Dermatology 2010;62(6):1069-71. [PUBMED: 20466185]
281. Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology 2009;23(8):876-82. [PUBMED: 19508315]
282. Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. British Journal of Dermatology 2007;157(3):474-81. [PUBMED: 17596156]
283. Landow K. Rosacea: The battle goes on. Comprehensive Therapy 2005;31(2):145-58. [PUBMED: 15901945]
284. Layton A, Thiboutot D. Emerging therapies in rosacea. Journal of the American Academy of Dermatology 2013;69(6 Suppl 1):S57-65. [PUBMED: 24229638]
285. Lazaridou E, Fotiadou C, Ziakas NG, Giannopoulou C, Apalla Z, Ioannides D. Clinical and laboratory study of ocular rosacea in northern Greece. Journal of the European Academy of Dermatology and Venereology 2011;25(12):1428-31. [PUBMED: 21366706]
286. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis 2004;73(6 Suppl):11-7. [PUBMED: 15228129]
287. Marks R. The enigma of rosacea. Journal of Dermatological Treatment 2007;18(6):326-8. [PUBMED: 18058493]
288. Menezes N, Moreira A, Mota G, Baptista A. Quality of life and rosacea: Pulsed dye laser impact. Journal of Cosmetic & Laser Therapy 2009;11(3):139-41. [DOI: 10.1080/14764170902741311; PUBMED: 19462330]
289. Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. Journal of the American Academy of Dermatology 2014; Vol. 71, issue 5:973-80. [PUBMED: 24993600]
290. Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs 2014;74(13):1457-65. [PUBMED: 25154627]
291. Narayanan S, Hünerbein A, Getie M, Jäckel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. Journal of Pharmacy and Pharmacology 2007;59(8):1125-30. [PUBMED: 17725855]
292. Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. Journal of the American Academy of Dermatology 2007;57(2):213-21. [PUBMED: 17445948]
293. Nickle SB, Peterson N, Peterson M. Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin. Journal of Clinical and Aesthetic Dermatology 2014;7(4):22-34. [PUBMED: 24765227]
294. Oltz M, Check J. Rosacea and its ocular manifestations. Optometry 2011;82(2):92-103. [PUBMED: 21276570]
295. Powell FC. Clinical practice. Rosacea. New England Journal of Medicine 2005;352(8):793-803. [PUBMED: 15728812]
296. Reinholz M, Tietze JK, Kilian K, Schaller M, Schöfer H, Lehmann P, et al. Rosacea - S1 guideline. Journal der Deutschen Dermatologischen Gesellschaft 2013;11(8):768-90. [PUBMED: 23647643]
297. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
298. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology 2006;54(2):258-65. [PUBMED: 16443056]
299. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: 7823387]
300. Schünemann H, Brozek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. www.cc-ims.net/gradepro. Version 3.2 [updated March 2009] 2009.
301. Shim TN, Abdullah A. The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. Journal of Clinical and Aesthetic Dermatology 2013;6(4):30-2. [PUBMED: 23630639]
302. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opinion on Drug Safety 2008;7(5):571-7. [PUBMED: 18759709]
303. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. Journal of Investigative Dermatology 2011;15(1):2-11. [PUBMED: 22076321]
304. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. Journal of the American Academy of Dermatology 2013;69(6 Suppl 1):S15-26. [PUBMED: 24229632]
305. Stone DU, Chodosh J. Oral tetracyclines for ocular rosacea: An evidence-based review of the literature. Cornea 2004;23(1):106-9. [PUBMED: 14701969]
306. Taghizadeh R, Mackay SP, Gilbert PM. Treatment of rhinophyma with the Versajet Hydrosurgery System. Journal of Plastic, Reconstructive & Aesthetic Surgery 2008;61(3):330-3. [PUBMED: 18267312]
307. Tan J, Blume-Peytavi U, Ortonne JP, Wilhelm K, Marticou L, Baltas E, et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. British Journal of Dermatology 2013;169(3):555-62. [PUBMED: 23600367]
308. Tan J, Berg M. Rosacea: current state of epidemiology. Journal of the American Academy of Dermatology 2013;69(6 Suppl 1):S27-35. [PUBMED: 24229634]
309. Tan J, Liu H, Leyden JJ, Leoni MJ. Reliability of Clinician Erythema Assessment grading scale. Journal of the American Academy of Dermatology 2014; Vol. 71, issue 4:760-3. [PUBMED: 24999270]
310. Tanghetti E, Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis 2014;93(2):71-6. [PUBMED: 24605343]
311. Thiboutot DM. Acne and rosacea. New and emerging therapies. Dermatologic Clinics 2000;18(1):63-71. [PUBMED: 10626112]
312. Tisma VS, Basta-Juzbasic A, Jaganjac M, Brcic L, Dobric I, Lipozencic J, et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. Journal of the American Academy of Dermatology 2009;60(2):270-6. [PUBMED: 19028405]
313. Treadwell, JT, Tregear SJ, Reston JT, Turkelson CM. A system for rating the stability and strength of medical evidence. BMC Medical Research Methodology 2006;6:52.
314. Uslu M, Şavk E, Karaman G, Şendur N. Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements. Acta Dermato-Venereologica 2012;92(1):73-7. [PUBMED: 21952746]
315. van der Linden MM, van Rappard DC, Daams JG, Sprangers MA, Spuls PI, de Korte J. Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review. Acta Dermato-Venereologica 2014 Oct 1 [Epub ahead of print]. [PUBMED: 25270577]
316. van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD007628.pub3]
317. van Zuuren EJ, Fedorowicz Z. Lack of 'appropriately assessed' patient-reported outcomes in randomized controlled trials assessing the effectiveness of interventions for rosacea. British Journal of Dermatology 2013;168(2):442-4. [PUBMED: 22803770]
318. Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. Journal of the American Academy of Dermatology 2013;69(6 Suppl 1):S36-41. [PUBMED: 24229635]
319. Walker C, Webster G. A multicenter, double-blind, randomized trial to evaluate long-term anti-inflammatory dose doxycycline (40 mg) therapy: Results of the lack of effect on bacterial flora. Presented at: Fall Clinical Dermatology Conference. Las Vegas, NV, USA, 7-11 October 2006. 2006.
320. Wilkin JK. Rosacea. Pathophysiology and treatment. Archives of Dermatology 1994;130(3):359-62. [EMBASE: 1994109375]
321. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Journal of the American Academy of Dermatology 2002;46(4):584-7. [MEDLINE: 11907512]
322. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology 2004;50(6):907-12. [PUBMED: 15153893]
323. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine 2007;13(8):975-80. [PUBMED: 17676051]
324. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. Journal of Investigative Dermatology. Symposium Proceedings / the Society for Investigative Dermatology, Inc. European Society for Dermatological Research 2011;15(1):12-5. [PUBMED: 22076322]
325. van Zuuren EJ, Powell FC, Graber M. Interventions for rosacea. Cochrane Database of Systematic Reviews 2000, Issue 12. [DOI: 10.1002/14651858.CD003262]
326. van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK. Interventions for rosacea. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003262.pub2; PUBMED: 14974010]
327. van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003262.pub3; PUBMED: 16034895]
328. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. Journal of the American Academy of Dermatology 2007;56(1):107-15. [PUBMED: 17190628]
329. van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z. Interventions for rosacea. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD003262.pub4]